BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place ...

New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its ...

BioNTech SE (NASDAQ:BNTX) shares rose 6.4% in pre-market trading on Monday after the company reported updated survival data ...

BioNTech and partner OncoC4's anti-CTLA-4 immunotherapy gotistobart almost doubled survival in a trial involving patients with a hard-to-treat form of lung cancer, ahead of a pivotal readout due next ...

Gotistobart continues to show potential aschemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

BioNTech SE has already presented new clinical data from its broad lung cancer pipeline at the 2026 IASLC World Conference on Lung Cancer in Seoul, covering key assets pumitamig, gotistobart and ...

In stage I, 87 patients progressed after immunotherapy and chemotherapy and were randomised to two groups.

BioNTech's gotistobart nearly doubled median survival in a Phase 3 lung cancer trial, but a guidance cut and CEO succession keep the story two-sided. BioNTech's Pipeline Delivers in Seoul While the ...

Multiple milestones achieved in 2026, including initiation of six pivotal trials - five for pumitamig and one for B7-H3-targeting ADC candidate elfetabart drozuntecan; upcoming 2026 catalysts include ...

On Monday, BioNTech SE BNTX and OncoC4 Inc. released the first median overall survival results from stage 1 of their global ...